Serlopitant is a small molecule antagonist of neurokinin-1 (NK1-R), the primary endogenous receptor for the neuropeptide, Substance P (SP). The importance of SP and NK1 receptor as mediators of pruritus and cough signaling have been demonstrated in multiple animal models and human clinical trials. Serlopitant is administered orally once daily. Serlopitant has been administered to over 1000 individuals to date and has shown benefit in two completed phase 2 studies in pruritic conditions.

News Releases